The Massachusetts Department of Public Health (DPH) has issued a new warning about medetomidine, a powerful veterinary sedative increasingly being found in the unregulated opioid supply. While fentanyl remains a primary driver of overdose deaths, the presence of additional substances like medetomidine is creating new risks for people who use drugs, including dangerous complications during overdose and withdrawal.
In an October 21, 2026 clinical advisory, Massachusetts DPH confirmed that medetomidine has been detected in drug samples throughout the state, with several patients requiring hospitalization for severe withdrawal.
Here’s what you should know about medetomidine, its effects, and why health officials are increasingly concerned about its presence in the opioid supply.
What Is Medetomidine?
Medetomidine is a powerful sedative used in veterinary medicine, primarily to sedate animals and provide pain relief during medical procedures. It belongs to a class of medications known as alpha-2 adrenergic agonists, which affect the central nervous system and can significantly reduce heart rate, blood pressure, and alertness.
Although medetomidine is not approved for human use, a related medication called dexmedetomidine is used in controlled medical settings. Medetomidine itself has increasingly appeared in the illicit drug supply, most commonly mixed with illegally manufactured fentanyl.
Sometimes referred to by street names such as “rhino tranq,” “mede,” or “dex,” medetomidine may be present without a person’s knowledge. Someone purchasing what they believe to be fentanyl or another opioid may unknowingly consume multiple substances with different effects and potentially dangerous interactions.
This unpredictability is one of the biggest concerns surrounding the emergence of medetomidine.
Medetomidine Found Throughout Massachusetts
According to the Massachusetts DPH, medetomidine was first identified in the state’s unregulated opioid supply in June 2024. Since then, it has been detected in samples from every Massachusetts county, with the highest concentration of detections in Central and Western Massachusetts.
The October 2026 advisory also reports that multiple patients were hospitalized and treated for medetomidine withdrawal in the Boston and Springfield/Holyoke regions during the spring of 2026. Additional suspected cases have been identified in emergency departments and hospital settings.
This is not exclusively a Massachusetts problem. In April 2026, the Centers for Disease Control and Prevention (CDC) issued a national health advisory warning of increasing medetomidine detections throughout the United States.
According to the CDC, forensic laboratory reports involving medetomidine increased from 247 in 2023 to 8,233 in 2025. More than half of those reports came from the Northeast, underscoring the growing concern for communities across Massachusetts and neighboring states.
What Are the Effects and Dangers of Medetomidine?
One of the primary dangers of medetomidine is its ability to cause profound and prolonged sedation. A person exposed to the drug may become extremely drowsy, unresponsive, or difficult to awaken. Medetomidine can also cause dangerously slow heart rates and low blood pressure.
When mixed with fentanyl, these effects can complicate an already life-threatening opioid overdose.
Naloxone, commonly known by the brand name Narcan, can reverse the opioid effects of fentanyl and help restore breathing. However, naloxone does not reverse medetomidine’s sedative effects.
This means someone experiencing an overdose involving both substances may begin breathing normally after receiving naloxone but remain heavily sedated or unresponsive because of medetomidine.
Importantly, naloxone should still be administered whenever an opioid overdose is suspected. Fentanyl is frequently present alongside medetomidine, and reversing its effects can save a life. Emergency medical attention is necessary even if naloxone appears to work.
Learn more about how to use Narcan during an opioid overdose.
Medetomidine Withdrawal: Symptoms and Complications
While medetomidine’s sedative effects are dangerous, withdrawal has emerged as another serious concern.
People who are repeatedly exposed to medetomidine can develop physical dependence. When they stop using substances containing the drug, they may experience severe withdrawals that differ from typical opioid withdrawal.
According to Massachusetts DPH and the CDC, medetomidine withdrawal symptoms can include:
- Severe nausea and vomiting, sometimes difficult to control
- Rapid heart rate and dangerously high blood pressure
- Tremors, shaking, and involuntary muscle movements
- Profuse sweating, anxiety, and agitation
- Fluctuating alertness or reduced responsiveness
- Chest pain and other signs of cardiovascular distress
These symptoms can develop rapidly, sometimes within hours of the last use. The CDC reports that withdrawal symptoms may peak approximately 18 to 36 hours after stopping.
In severe cases, medetomidine withdrawal can lead to hypertensive emergencies, abnormal heart rhythms, heart attacks, strokes, and other life-threatening complications.
Another important concern is that people exposed to medetomidine and fentanyl may experience withdrawal from both substances simultaneously. Standard opioid withdrawal medications alone may not adequately address medetomidine withdrawal, making medical evaluation and appropriate monitoring particularly important.
Anyone experiencing suspected medetomidine withdrawal should seek medical attention immediately rather than attempting to manage severe symptoms independently.
Is Medetomidine the Same as Xylazine?
Medetomidine and xylazine are different substances, although both are veterinary sedatives that have been identified in the illicit opioid supply.
Xylazine, commonly called “tranq,” has received considerable attention in recent years because of its association with fentanyl overdoses and severe skin wounds.
Like xylazine, medetomidine can cause profound sedation and does not respond directly to naloxone. However, medetomidine is generally more potent and longer-lasting, and its withdrawal symptoms can be particularly severe.
The CDC has also noted that, unlike xylazine, medetomidine has not been clearly associated with the same pattern of skin wounds. Both substances demonstrate how the dangers of the unregulated opioid supply extend beyond fentanyl alone.
Getting Help for Opioid Addiction in Massachusetts
At Northstar Recovery Center, we provide comprehensive fentanyl and opioid addiction treatment for adults throughout Massachusetts. Our programs include Day Treatment (PHP), Intensive Outpatient Treatment (IOP), individual and group therapy, and medication-assisted treatment when clinically appropriate.
With locations in Southborough and West Springfield, along with virtual treatment options, we help people find a level of care that meets their needs. We also coordinate referrals to medical detox facilities when a higher level of care is necessary.
If you or someone you love is struggling with opioid addiction, call 888-339-5756 to speak confidentially with our admissions team about available treatment options.
Frequently Asked Questions About Medetomidine
Can Narcan Reverse a Medetomidine Overdose?
Narcan (naloxone) does not reverse medetomidine itself because medetomidine is not an opioid. However, medetomidine is frequently mixed with fentanyl, and naloxone can reverse the opioid-related effects, including dangerous respiratory depression. Always administer naloxone when an opioid overdose is suspected and call 911.
How Long Does Medetomidine Withdrawal Last?
The timeline varies depending on the extent of exposure, other substances involved, and individual health factors. Withdrawal may begin within hours of the last use, with symptoms potentially peaking between 18 and 36 hours later. There is no established timeline that applies to everyone, and severe cases may require hospitalization and several days of medical management.
Can Medetomidine Be Detected on a Drug Test?
Medetomidine is not typically included in standard hospital drug screens or routine workplace drug tests. Specialized laboratory testing can identify medetomidine or its metabolites, but these tests may not be readily available and results can take time. Healthcare professionals should be informed about possible medetomidine exposure when evaluating suspected overdose or withdrawal.
